[424B5] Eyenovia, Inc. Prospectus Supplement (Debt Securities)
Eyenovia, Inc. (Nasdaq: EYEN) has filed a Prospectus Supplement under Form 424B5 to update its existing at-the-market (ATM) equity program with Chardan Capital Markets. The filing registers the offer and sale of up to $14,942,887 in additional common stock, a figure calculated to comply with General Instruction I.B.6 of Form S-3.
• As of 27 June 2025, the company’s non-affiliate public float was approximately $52.8 million, based on 4,853,092 shares at $10.88 per share.
• I.B.6 limits primary offerings to one-third of that float—about $17.6 million—within any 12-month period when the float is under $75 million.
• Eyenovia has already sold $2.66 million of securities during the preceding 12 months, leaving capacity for the newly registered $14.94 million.
The filing does not alter the total $50 million ceiling of the December 30, 2024 amended Sales Agreement, but it refreshes the amount currently eligible for issuance. Shares will be sold from time to time through Chardan acting as sales agent, at market prices on Nasdaq Capital Market under the symbol EYEN.
The supplement reiterates that investment in EYEN entails a high degree of risk and directs investors to previously filed risk factors in the company’s 10-K and 8-K dated 27 June 2025.
Eyenovia, Inc. (Nasdaq: EYEN) ha presentato un Supplemento al Prospetto secondo il Modulo 424B5 per aggiornare il suo programma di equity at-the-market (ATM) esistente con Chardan Capital Markets. La registrazione riguarda l'offerta e la vendita di un massimo di 14.942.887 $ in azioni ordinarie aggiuntive, cifra calcolata per rispettare la Istruzione Generale I.B.6 del Modulo S-3.
• Al 27 giugno 2025, il flottante pubblico non affiliato della società era di circa 52,8 milioni di $, basato su 4.853.092 azioni al prezzo di 10,88 $ per azione.
• La regola I.B.6 limita le offerte principali a un terzo di tale flottante—circa 17,6 milioni di $—in un periodo di 12 mesi quando il flottante è inferiore a 75 milioni di $.
• Eyenovia ha già venduto 2,66 milioni di $ di titoli nei 12 mesi precedenti, lasciando una capacità residua per i nuovi 14,94 milioni di $ registrati.
La registrazione non modifica il tetto totale di 50 milioni di $ previsto dall'Accordo di Vendita emendato al 30 dicembre 2024, ma aggiorna l'importo attualmente disponibile per l'emissione. Le azioni saranno vendute di volta in volta tramite Chardan, che agirà come agente di vendita, a prezzi di mercato sul Nasdaq Capital Market con il simbolo EYEN.
Il supplemento ribadisce che l'investimento in EYEN comporta un alto livello di rischio e indirizza gli investitori ai fattori di rischio precedentemente presentati nei documenti 10-K e 8-K datati 27 giugno 2025.
Eyenovia, Inc. (Nasdaq: EYEN) ha presentado un Suplemento al Prospecto bajo el formulario 424B5 para actualizar su programa de acciones en el mercado (ATM) existente con Chardan Capital Markets. La presentación registra la oferta y venta de hasta 14.942.887 $ en acciones comunes adicionales, cifra calculada para cumplir con la Instrucción General I.B.6 del Formulario S-3.
• Al 27 de junio de 2025, el flotante público no afiliado de la compañía era aproximadamente 52,8 millones de $, basado en 4.853.092 acciones a 10,88 $ por acción.
• La regla I.B.6 limita las ofertas primarias a un tercio de ese flotante—aproximadamente 17,6 millones de $—en cualquier período de 12 meses cuando el flotante es menor a 75 millones de $.
• Eyenovia ya ha vendido 2,66 millones de $ en valores durante los 12 meses anteriores, dejando capacidad para los nuevos 14,94 millones de $ registrados.
La presentación no altera el techo total de 50 millones de $ del Acuerdo de Venta modificado al 30 de diciembre de 2024, pero actualiza la cantidad actualmente elegible para emisión. Las acciones se venderán ocasionalmente a través de Chardan, actuando como agente de ventas, a precios de mercado en Nasdaq Capital Market bajo el símbolo EYEN.
El suplemento reitera que invertir en EYEN implica un alto grado de riesgo y dirige a los inversores a los factores de riesgo presentados previamente en los informes 10-K y 8-K con fecha 27 de junio de 2025.
Eyenovia, Inc. (나스닥: EYEN)는 기존의 시장가 매도(ATM) 주식 프로그램을 업데이트하기 위해 Form 424B5에 따른 추가 설명서(Prospectus Supplement)를 제출했습니다. 이번 제출은 일반 지침 I.B.6 (Form S-3)을 준수하기 위해 계산된 최대 14,942,887 달러 상당의 추가 보통주 발행 및 판매를 등록하는 내용입니다.
• 2025년 6월 27일 기준, 회사의 비계열 공개 유통 주식 가치는 약 5,280만 달러로, 4,853,092주를 주당 10.88달러로 산정했습니다.
• I.B.6 규정은 유통 주식가치가 7,500만 달러 미만인 경우 12개월 내에 1/3인 약 1,760만 달러까지 1차 공모를 제한합니다.
• Eyenovia는 지난 12개월 동안 이미 266만 달러 상당의 증권을 판매하여, 이번에 등록한 1,494만 달러의 발행 여력이 남아있습니다.
이번 제출은 2024년 12월 30일 수정된 판매 계약의 총 5,000만 달러 한도를 변경하지 않지만, 현재 발행 가능한 금액을 갱신합니다. 주식은 Chardan이 판매 대리인으로서 나스닥 캐피털 마켓에서 EYEN 심볼로 시장 가격에 따라 수시로 판매할 예정입니다.
추가 설명서는 EYEN 투자에 높은 위험성이 수반됨을 재차 강조하며, 투자자들에게 2025년 6월 27일자 10-K 및 8-K 보고서에 기재된 위험 요소를 참고할 것을 안내합니다.
Eyenovia, Inc. (Nasdaq : EYEN) a déposé un Supplément au Prospectus sous le formulaire 424B5 afin de mettre à jour son programme d’actions at-the-market (ATM) existant avec Chardan Capital Markets. Le dépôt enregistre l’offre et la vente pouvant atteindre 14 942 887 $ d’actions ordinaires supplémentaires, un montant calculé pour se conformer à la Instruction Générale I.B.6 du formulaire S-3.
• Au 27 juin 2025, le flottant public non affilié de la société était d’environ 52,8 millions $, basé sur 4 853 092 actions à 10,88 $ par action.
• La règle I.B.6 limite les offres principales à un tiers de ce flottant—environ 17,6 millions $—sur une période de 12 mois lorsque le flottant est inférieur à 75 millions $.
• Eyenovia a déjà vendu pour 2,66 millions $ de titres au cours des 12 mois précédents, laissant une capacité pour les 14,94 millions $ nouvellement enregistrés.
Le dépôt ne modifie pas le plafond total de 50 millions $ de l’accord de vente modifié au 30 décembre 2024, mais il actualise le montant actuellement éligible à l’émission. Les actions seront vendues de temps à autre par l’intermédiaire de Chardan, agissant en tant qu’agent de vente, aux prix du marché sur le Nasdaq Capital Market sous le symbole EYEN.
Le supplément rappelle que l’investissement dans EYEN comporte un niveau élevé de risque et invite les investisseurs à consulter les facteurs de risque précédemment déposés dans les rapports 10-K et 8-K datés du 27 juin 2025.
Eyenovia, Inc. (Nasdaq: EYEN) hat einen Prospektergänzungsbericht gemäß Formular 424B5 eingereicht, um sein bestehendes At-the-Market (ATM) Aktienprogramm mit Chardan Capital Markets zu aktualisieren. Die Einreichung registriert das Angebot und den Verkauf von bis zu 14.942.887 $ zusätzlicher Stammaktien, eine Summe, die gemäß der Allgemeinen Anweisung I.B.6 des Formulars S-3 berechnet wurde.
• Zum 27. Juni 2025 betrug der nicht verbundene Streubesitz des Unternehmens etwa 52,8 Millionen $, basierend auf 4.853.092 Aktien zu je 10,88 $.
• I.B.6 begrenzt Primärangebote auf ein Drittel dieses Streubesitzes—etwa 17,6 Millionen $—innerhalb von 12 Monaten, wenn der Streubesitz unter 75 Millionen $ liegt.
• Eyenovia hat in den vorangegangenen 12 Monaten bereits Wertpapiere im Wert von 2,66 Millionen $ verkauft, sodass noch Kapazität für die neu registrierten 14,94 Millionen $ besteht.
Die Einreichung ändert nicht die Gesamthöchstgrenze von 50 Millionen $ des am 30. Dezember 2024 geänderten Verkaufsvertrags, aktualisiert jedoch den aktuell ausgebbaren Betrag. Die Aktien werden gelegentlich über Chardan als Verkaufsagent zum Marktpreis an der Nasdaq Capital Market unter dem Symbol EYEN verkauft.
Der Ergänzungsbericht betont erneut, dass eine Investition in EYEN mit einem hohen Risiko verbunden ist, und verweist Anleger auf zuvor eingereichte Risikofaktoren in den 10-K- und 8-K-Berichten vom 27. Juni 2025.
- Enhanced liquidity runway: registration enables up to $14.94 million in additional capital without negotiating new terms.
- No discounts or warrants disclosed: shares will be sold at prevailing market prices through an established ATM mechanism.
- Potential shareholder dilution: new shares will increase the outstanding share count, pressuring EPS and ownership percentages.
- Small public float: issuing one-third of float within 12 months could create supply overhang and weigh on share price.
Insights
TL;DR – ATM capacity refreshed; modest dilution risk, improves liquidity.
This prospectus supplement merely resets Eyenovia’s ATM shelf to the maximum amount presently allowed under the I.B.6 safe-harbor. The company can now issue up to $14.94 million in common stock, having already tapped $2.66 million of capacity in the last 12 months. Operational cash runway should improve if shares are sold, but existing holders face incremental dilution. No use-of-proceeds detail is provided, suggesting funds will serve general corporate purposes. Because the aggregate float is small (<$75 million), successive ATM sales can noticeably pressure the share price. Still, the filing is routine and contains no negative surprises such as warrant resets or discounted structures.
TL;DR – Standard shelf update; neutral unless heavy issuance ensues.
For a micro-cap biotech, ATM flexibility is vital. By refreshing capacity, EYEN maintains optionality to raise ~28% of its public float at-market, mitigating financing risk without committing to a block discount. Dilution impact will depend on actual take-down pace and prevailing share price, neither of which is specified. The supplement adds no new fundamental data—no clinical, revenue, or guidance updates—so immediate valuation effect is limited. I view the disclosure as administrative rather than catalytic; rating remains Neutral.
Eyenovia, Inc. (Nasdaq: EYEN) ha presentato un Supplemento al Prospetto secondo il Modulo 424B5 per aggiornare il suo programma di equity at-the-market (ATM) esistente con Chardan Capital Markets. La registrazione riguarda l'offerta e la vendita di un massimo di 14.942.887 $ in azioni ordinarie aggiuntive, cifra calcolata per rispettare la Istruzione Generale I.B.6 del Modulo S-3.
• Al 27 giugno 2025, il flottante pubblico non affiliato della società era di circa 52,8 milioni di $, basato su 4.853.092 azioni al prezzo di 10,88 $ per azione.
• La regola I.B.6 limita le offerte principali a un terzo di tale flottante—circa 17,6 milioni di $—in un periodo di 12 mesi quando il flottante è inferiore a 75 milioni di $.
• Eyenovia ha già venduto 2,66 milioni di $ di titoli nei 12 mesi precedenti, lasciando una capacità residua per i nuovi 14,94 milioni di $ registrati.
La registrazione non modifica il tetto totale di 50 milioni di $ previsto dall'Accordo di Vendita emendato al 30 dicembre 2024, ma aggiorna l'importo attualmente disponibile per l'emissione. Le azioni saranno vendute di volta in volta tramite Chardan, che agirà come agente di vendita, a prezzi di mercato sul Nasdaq Capital Market con il simbolo EYEN.
Il supplemento ribadisce che l'investimento in EYEN comporta un alto livello di rischio e indirizza gli investitori ai fattori di rischio precedentemente presentati nei documenti 10-K e 8-K datati 27 giugno 2025.
Eyenovia, Inc. (Nasdaq: EYEN) ha presentado un Suplemento al Prospecto bajo el formulario 424B5 para actualizar su programa de acciones en el mercado (ATM) existente con Chardan Capital Markets. La presentación registra la oferta y venta de hasta 14.942.887 $ en acciones comunes adicionales, cifra calculada para cumplir con la Instrucción General I.B.6 del Formulario S-3.
• Al 27 de junio de 2025, el flotante público no afiliado de la compañía era aproximadamente 52,8 millones de $, basado en 4.853.092 acciones a 10,88 $ por acción.
• La regla I.B.6 limita las ofertas primarias a un tercio de ese flotante—aproximadamente 17,6 millones de $—en cualquier período de 12 meses cuando el flotante es menor a 75 millones de $.
• Eyenovia ya ha vendido 2,66 millones de $ en valores durante los 12 meses anteriores, dejando capacidad para los nuevos 14,94 millones de $ registrados.
La presentación no altera el techo total de 50 millones de $ del Acuerdo de Venta modificado al 30 de diciembre de 2024, pero actualiza la cantidad actualmente elegible para emisión. Las acciones se venderán ocasionalmente a través de Chardan, actuando como agente de ventas, a precios de mercado en Nasdaq Capital Market bajo el símbolo EYEN.
El suplemento reitera que invertir en EYEN implica un alto grado de riesgo y dirige a los inversores a los factores de riesgo presentados previamente en los informes 10-K y 8-K con fecha 27 de junio de 2025.
Eyenovia, Inc. (나스닥: EYEN)는 기존의 시장가 매도(ATM) 주식 프로그램을 업데이트하기 위해 Form 424B5에 따른 추가 설명서(Prospectus Supplement)를 제출했습니다. 이번 제출은 일반 지침 I.B.6 (Form S-3)을 준수하기 위해 계산된 최대 14,942,887 달러 상당의 추가 보통주 발행 및 판매를 등록하는 내용입니다.
• 2025년 6월 27일 기준, 회사의 비계열 공개 유통 주식 가치는 약 5,280만 달러로, 4,853,092주를 주당 10.88달러로 산정했습니다.
• I.B.6 규정은 유통 주식가치가 7,500만 달러 미만인 경우 12개월 내에 1/3인 약 1,760만 달러까지 1차 공모를 제한합니다.
• Eyenovia는 지난 12개월 동안 이미 266만 달러 상당의 증권을 판매하여, 이번에 등록한 1,494만 달러의 발행 여력이 남아있습니다.
이번 제출은 2024년 12월 30일 수정된 판매 계약의 총 5,000만 달러 한도를 변경하지 않지만, 현재 발행 가능한 금액을 갱신합니다. 주식은 Chardan이 판매 대리인으로서 나스닥 캐피털 마켓에서 EYEN 심볼로 시장 가격에 따라 수시로 판매할 예정입니다.
추가 설명서는 EYEN 투자에 높은 위험성이 수반됨을 재차 강조하며, 투자자들에게 2025년 6월 27일자 10-K 및 8-K 보고서에 기재된 위험 요소를 참고할 것을 안내합니다.
Eyenovia, Inc. (Nasdaq : EYEN) a déposé un Supplément au Prospectus sous le formulaire 424B5 afin de mettre à jour son programme d’actions at-the-market (ATM) existant avec Chardan Capital Markets. Le dépôt enregistre l’offre et la vente pouvant atteindre 14 942 887 $ d’actions ordinaires supplémentaires, un montant calculé pour se conformer à la Instruction Générale I.B.6 du formulaire S-3.
• Au 27 juin 2025, le flottant public non affilié de la société était d’environ 52,8 millions $, basé sur 4 853 092 actions à 10,88 $ par action.
• La règle I.B.6 limite les offres principales à un tiers de ce flottant—environ 17,6 millions $—sur une période de 12 mois lorsque le flottant est inférieur à 75 millions $.
• Eyenovia a déjà vendu pour 2,66 millions $ de titres au cours des 12 mois précédents, laissant une capacité pour les 14,94 millions $ nouvellement enregistrés.
Le dépôt ne modifie pas le plafond total de 50 millions $ de l’accord de vente modifié au 30 décembre 2024, mais il actualise le montant actuellement éligible à l’émission. Les actions seront vendues de temps à autre par l’intermédiaire de Chardan, agissant en tant qu’agent de vente, aux prix du marché sur le Nasdaq Capital Market sous le symbole EYEN.
Le supplément rappelle que l’investissement dans EYEN comporte un niveau élevé de risque et invite les investisseurs à consulter les facteurs de risque précédemment déposés dans les rapports 10-K et 8-K datés du 27 juin 2025.
Eyenovia, Inc. (Nasdaq: EYEN) hat einen Prospektergänzungsbericht gemäß Formular 424B5 eingereicht, um sein bestehendes At-the-Market (ATM) Aktienprogramm mit Chardan Capital Markets zu aktualisieren. Die Einreichung registriert das Angebot und den Verkauf von bis zu 14.942.887 $ zusätzlicher Stammaktien, eine Summe, die gemäß der Allgemeinen Anweisung I.B.6 des Formulars S-3 berechnet wurde.
• Zum 27. Juni 2025 betrug der nicht verbundene Streubesitz des Unternehmens etwa 52,8 Millionen $, basierend auf 4.853.092 Aktien zu je 10,88 $.
• I.B.6 begrenzt Primärangebote auf ein Drittel dieses Streubesitzes—etwa 17,6 Millionen $—innerhalb von 12 Monaten, wenn der Streubesitz unter 75 Millionen $ liegt.
• Eyenovia hat in den vorangegangenen 12 Monaten bereits Wertpapiere im Wert von 2,66 Millionen $ verkauft, sodass noch Kapazität für die neu registrierten 14,94 Millionen $ besteht.
Die Einreichung ändert nicht die Gesamthöchstgrenze von 50 Millionen $ des am 30. Dezember 2024 geänderten Verkaufsvertrags, aktualisiert jedoch den aktuell ausgebbaren Betrag. Die Aktien werden gelegentlich über Chardan als Verkaufsagent zum Marktpreis an der Nasdaq Capital Market unter dem Symbol EYEN verkauft.
Der Ergänzungsbericht betont erneut, dass eine Investition in EYEN mit einem hohen Risiko verbunden ist, und verweist Anleger auf zuvor eingereichte Risikofaktoren in den 10-K- und 8-K-Berichten vom 27. Juni 2025.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-282458
Prospectus
Supplement
(To Prospectus Supplements Dated June 2, 2025, April 17, 2025 and December 30, 2024
To Prospectus dated October 8, 2024)
Up to $14,942,887
of
Common Stock
This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus dated October 8, 2024 (the “Prior Prospectus”), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-282458) (the “Registration Statement”), as previously supplemented by the prospectus supplements dated December 30, 2024, April 17, 2025 and June 2, 2025 (together with the Prior Prospectus, the “Prospectus”). This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto.
We previously entered into an amended and restated sales agreement (the “Sales Agreement”) with Chardan Capital Markets, LLC (“Chardan”), dated as of December 30, 2024, relating to the offer and sale of shares of our common stock, $0.0001 par value per share (the “common stock”), having an aggregate offering price of up to $50,000,000 from time to time through Chardan acting as our agent.
We are filing this Prospectus Supplement to amend the Prospectus to update the amount of shares we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the Sales Agreement. As of June 27, 2025, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was approximately $52,801,640, which was calculated based on 4,853,092 shares of our outstanding common stock held by non-affiliates on June 27, 2025 at a price of $10.88 per share, the closing price of our common stock on June 27, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell, pursuant to the Registration Statement of which this Prospectus Supplement and the Prospectus form a part, securities in a public primary offering with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this Prospectus Supplement, we have sold approximately $2,657,659 of securities pursuant to General Instruction I.B.6 of Form S-3. As a result of the limitations of General Instruction I.B.6, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering price of up to $14,942,887 from time to time through Chardan.
Our common stock is listed on The Nasdaq Capital Market under the symbol “EYEN.” On June 27, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $10.88 per share.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-6 of the Prospectus, the “Risk Factors” section in our most recent Annual Report on Form 10-K and in our Current Report on Form 8-K filed on June 27, 2025, each of which is incorporated by reference into this Prospectus Supplement and the Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this Prospectus Supplement and the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement or the Prospectus. Any representation to the contrary is a criminal offense.
Chardan
The date of this Prospectus Supplement is June 27, 2025.
FAQ
Why did Eyenovia (EYEN) file this new 424B5 prospectus supplement?
How much stock has EYEN already sold under the current ATM in the last 12 months?
What is the maximum EYEN can sell under Form S-3 I.B.6?
What is EYEN’s public float as of 27 June 2025?
Will existing shareholders face dilution from the new ATM capacity?
